skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Overview
Datamonitor Healthcare uses a patient-based approach to size the commercial potential of Alzheimer’s disease across the US, Japan, and the five major EU markets (France, Germany, Italy, Spain, and the UK) from 2012 to 2021.

Highlights
Alzheimer’s disease across the US, Japan, and five major EU markets is set to double in value over the next 10 years. The catalysts for this growth include an increasingly elderly population, earlier and improved diagnosis, and the introduction of new therapeutic classes.

Pfizer/Eisai’s Aricept, formerly the highest selling brand in the market, has been overtaken by Forest/Lundbeck/Merz’s Namenda (memantine). The two drugs are following differing growth trajectories: Namenda’s sales will continue to rise while Aricept’s revenues are severely eroded by generic competition.

The beta amyloid immunotherapy solanezumab has the potential to grow the market by $4.6bn. Datamonitor Healthcare forecasts that around 330,000 patients with mild cognitive impairment or mild to moderate Alzheimer’s disease will receive immunotherapies annually by 2021 in the US, Japan, and the five major EU markets.

Methodology
Patient-based forecasting methodology utilizing epidemiology data and primary research with 133 neurologists across the US, Japan, and five major EU markets. Pricing, dosing, and future event assumptions are added to create Datamonitor Healthcare’s forecast.

 


This is an Alzheimer’s Disease analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.

Read also

  • Biomedtracker: see the drug development process through anal...

    Key Potential Drug Launches in 2022

    Released July 22, 2021. Contains information like likelihood of approval (LOA) ratings and upcoming catalysts that are current as of April 2021.

  • Biomedtracker: see the drug development process through anal...

    2020 Deal-Making Roundup

    Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.

    Topics Drug Review Coronavirus

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    2021 Post-ASCO Insights and Analysis

    The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

    Topics Cancer

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: